These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32599446)

  • 1. The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis.
    Kopelli E; Samara M; Siargkas A; Goulas A; Papazisis G; Chourdakis M
    Psychiatry Res; 2020 Sep; 291():113246. PubMed ID: 32599446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
    Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
    Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
    Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
    JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
    McGuire P; Robson P; Cubala WJ; Vasile D; Morrison PD; Barron R; Taylor A; Wright S
    Am J Psychiatry; 2018 Mar; 175(3):225-231. PubMed ID: 29241357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabidiol monotherapy for treatment-resistant schizophrenia.
    Zuardi AW; Hallak JE; Dursun SM; Morais SL; Sanches RF; Musty RE; Crippa JA
    J Psychopharmacol; 2006 Sep; 20(5):683-6. PubMed ID: 16401651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
    Smith RC; Leucht S; Davis JM
    Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis.
    Men P; Yi Z; Li C; Qu S; Xiong T; Yu X; Zhai S
    BMC Psychiatry; 2018 Sep; 18(1):286. PubMed ID: 30185173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials.
    Schneider-Thoma J; Efthimiou O; Huhn M; Krause M; Reichelt L; Röder H; Davis JM; Salanti G; Leucht S
    Lancet Psychiatry; 2018 Aug; 5(8):653-663. PubMed ID: 30042077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is cannabidiol an effective treatment for schizophrenia?
    Guinguis R; Ruiz MI; Rada G
    Medwave; 2017 Aug; 17(7):e7010. PubMed ID: 28820868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial.
    Dixon T; Cadenhead KS
    Trials; 2023 Nov; 24(1):775. PubMed ID: 38037108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modafinil for people with schizophrenia or related disorders.
    Ortiz-Orendain J; Covarrubias-Castillo SA; Vazquez-Alvarez AO; Castiello-de Obeso S; Arias Quiñones GE; Seegers M; Colunga-Lozano LE
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD008661. PubMed ID: 31828767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
    Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety.
    Lattanzi S; Brigo F; Trinka E; Zaccara G; Striano P; Del Giovane C; Silvestrini M
    CNS Drugs; 2020 Mar; 34(3):229-241. PubMed ID: 32040850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
    Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
    Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of the antipsychotic properties of cannabidiol in humans.
    Iseger TA; Bossong MG
    Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabidiol as a potential treatment for psychosis.
    Schubart CD; Sommer IE; Fusar-Poli P; de Witte L; Kahn RS; Boks MP
    Eur Neuropsychopharmacol; 2014 Jan; 24(1):51-64. PubMed ID: 24309088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyunsaturated fatty acid supplementation for schizophrenia.
    Joy CB; Mumby-Croft R; Joy LA
    Cochrane Database Syst Rev; 2003; (2):CD001257. PubMed ID: 12804400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis.
    Sakuma K; Matsunaga S; Nomura I; Okuya M; Kishi T; Iwata N
    Psychopharmacology (Berl); 2018 Aug; 235(8):2303-2314. PubMed ID: 29785555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia.
    Osborne AL; Solowij N; Weston-Green K
    Neurosci Biobehav Rev; 2017 Jan; 72():310-324. PubMed ID: 27884751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.